How has been the historical performance of Cravatex?
Cravatex has experienced significant declines in net sales and profitability, with net sales dropping from 594.33 Cr in Mar'22 to 173.76 Cr in Mar'25, and operating profit margins turning negative. Despite a reduction in total liabilities, the company has struggled to maintain revenue and profitability over recent years.
Answer:The historical performance of Cravatex shows significant fluctuations in its financial metrics over the years, particularly in net sales and profitability.Breakdown:
Cravatex's net sales have seen a downward trend from 594.33 Cr in Mar'22 to 173.76 Cr in Mar'25, indicating a substantial decline in revenue. The total operating income followed a similar pattern, decreasing from 778.67 Cr in Mar'20 to 173.76 Cr in Mar'25. The company's operating profit margins have been negative in recent years, with an operating profit of -1.69 Cr in Mar'25, compared to a positive 11.30 Cr in Mar'22. Profit before tax also dropped significantly from 58.33 Cr in Mar'23 to 6.37 Cr in Mar'25, while profit after tax remained stagnant at 4.83 Cr for both Mar'25 and Mar'24, down from 58.93 Cr in Mar'23. On the balance sheet, total liabilities decreased from 441.91 Cr in Mar'20 to 140.70 Cr in Mar'25, reflecting a reduction in long-term borrowings, which were eliminated by Mar'25. Total assets also decreased from 441.91 Cr in Mar'20 to 140.70 Cr in Mar'25, with cash and cash equivalents showing a slight increase to 75.45 Cr in Mar'25 from 56.32 Cr in Mar'23. Overall, Cravatex has faced challenges in maintaining revenue and profitability, while managing its liabilities effectively.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
